Biomarkers · Lipids & Apolipoproteins

Remnant Cholesterol

Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

Remnant Cholesterol and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death1.60×>=1.5 mmol/L vs <0.5 mmol/L nonfasting remnant cholesterol (stepwise categories) (95% CI 1.40–1.90) · Approximately 90 000 individuals from the Danish general population, up to 22 years of follow-up

Remnant Cholesterol by age and sex

Each bar runs from the 5th to the 95th percentile, the darker part from the 25th to the 75th, and the tick is the median. Not a reference range or a target.

The percentiles as a table

Each row is one sex and age band: the values below which 5%, 25%, 50%, 75% and 95% of people fall (mmol/L), from the survey named in the row. Not a reference range or a target.
Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	20-39	0.26	0.34	0.44	0.57	0.91	693	NHANES 2017-2018
All	40-59	0.31	0.39	0.52	0.68	0.98	746	NHANES 2017-2018
All	60+	0.34	0.41	0.52	0.65	0.88	909	NHANES 2017-2018
All	all	0.31	0.39	0.49	0.65	0.93	2,348	NHANES 2017-2018
Men	20-39	0.29	0.36	0.47	0.59	0.93	322	NHANES 2017-2018
Men	40-59	0.34	0.39	0.52	0.75	1.08	353	NHANES 2017-2018
Men	60+	0.34	0.41	0.54	0.67	0.87	460	NHANES 2017-2018
Men	all	0.31	0.39	0.49	0.67	0.98	1,135	NHANES 2017-2018
Women	20-39	0.23	0.34	0.39	0.57	0.85	371	NHANES 2017-2018
Women	40-59	0.31	0.39	0.51	0.65	0.92	393	NHANES 2017-2018
Women	60+	0.32	0.41	0.52	0.64	0.88	449	NHANES 2017-2018
Women	all	0.28	0.36	0.47	0.62	0.88	1,213	NHANES 2017-2018

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in Remnant Cholesterol, study by study

3 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
pharmacologic	Pemafibrate 0.2 mg twice daily in adults with type 2 diabetes, triglycerides 200-499 mg/dL, HDL-C <=40 mg/dL on lipid-lowering therapy (PROMINENT)	Remnant cholesterol 25.6% lower than placebo at 4 months (triglycerides -26.2%, apoC-III -27.6%), with no reduction in cardiovascular events	RCT	Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with…
pharmacologic	Levothyroxine titrated to normalise TSH for 12 months in adults >=65 with subclinical hypothyroidism (TRUST/IEMO pooled)	Remnant cholesterol -0.09 mmol/L (95% CI -0.16 to -0.01) with levothyroxine at 12 months, which the authors report as no overall effect	RCT	Ao L, Noordam R, Trompet S, et al. Levothyroxine treatment response of…
supplement	Daily Lacticaseibacillus paracasei 8700:2 at 10 billion CFU for 12 weeks in adults with metabolic syndrome	Remnant cholesterol reduced by 0.16 mmol/L (95% CI 0.02-0.29) more than placebo at 12 weeks, correlating with improved endothelial function	RCT	Yang J, Huang J, Huang Z, et al. Cardiometabolic benefits of Lacticaseibacillus…

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Genetic predisposition

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ GCKR rs1260326 (p.Pro446Leu) · CT or TT genotype vs CC genotype	+0.07 mmol/L	CT (46%) and TT (14%) vs CC (40%) genotype · General-population adults from Copenhagen	prospective cohort · PMID 21071687
↑ TRIB1 rs2954029 · TA or AA genotype vs TT genotype	+0.07 mmol/L	TA (50%) and AA (27%) vs TT (23%) genotype · General-population adults from Copenhagen	prospective cohort · PMID 21071687

Sources

Risk curve: Varbo A 2015 (PMID 25605681): all-cause HR 1.6 (1.4-1.9) >=1.5 mmol/L vs <0.5 mmol/L nonfasting remnant cholesterol (stepwise categories). Scaled to US values (NHANES).
Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90,000 individuals from the general population. Clin Chem. 2015;61(3):533-543.

Map Remnant Cholesterol against another biomarker.

Map Remnant Cholesterol against another marker